It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Evotec AG listed in MDAX
Nerina Coppini, 6 September 2018

Dual-listing of Evotec AG share in TecDAX and MDAX as of 24 September 2018 

Evotec and Celgene enter partnership in the field of targeted protein degradation
Nerina Coppini, 6 September 2018

The collaboration will focus on targeted protein degradation Evotec's panomics and data analytics platforms will be leveraged Financials include upfront payment as well as significant potential milestone-based payments and royalties

Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease
Nerina Coppini, 5 September 2018

First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease
Nerina Coppini, 30 August 2018

Strategic alliance with CHDI to accelerate development of drugs for Huntington's disease One of the largest strategic drug discovery alliances within Evotec 

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases
Nerina Coppini, 27 August 2018

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Nerina Coppini, 22 August 2018

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

Evotec partner Haplogen enters into collaboration with Bayer
Nerina Coppini, 14 August 2018

Focus on pulmonary diseases with high unmet medical need Integrated Haplogen-Bayer collaboration builds upon pulmonary portfolio created by Evotec and Haplogen Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Bayer to Haplogen

Evotec repays 50% of € 140 m acquisition loan
Nerina Coppini, 31 July 2018

Strong operational cashflow facilitates repayment of € 70 M within the first year of the loan term € 140 M loan was taken to expand Evotec's value chain with Aptuit in August 2017

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer
Nerina Coppini, 19 July 2018

Hamburg, Germany, 19 July 2018: Hamburg, Germany, 19 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting...

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development
Nerina Coppini, 3 July 2018

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard